TMEM41A and neoplasm: Furthermore, TMEM41A overexpression was associated with shorter PFI in EC patients with stages I, I-II, I-III, II-III, II-IV, III, and III-IV, weight > 80kg, height > 160cm, BMI, G2-3 grade, G3 grade, endometrioid, tumor invasion, age > 60 years, hormone therapy (no), radiotherapy (no), and diabetes (yes or no) (Fig 5).